The alliance will combine Intravacc’s vaccine development technology, WBVR’s viral vector and animal technologies, along with Utrecht University’s coronavirus expertise.

Intravacc noted that the intranasal vaccine will contain a Newcastle disease virus (NDV) vector that expresses the SARS-CoV-2’s immunogenic spike (S) protein, a key target for neutralising antibodies.

The company added that NDV demonstrated safety for intranasal or intratracheal delivery in mammals, including non-human primates.